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Abstract: The TGF superfamily growth factor BMP7 performs essential biological functions in embryonic development 
and regeneration of injured tissue in the adult. BMP7 activity is regulated at numerous levels in the signaling pathway by 
the expression of extracellular antagonists, decoy receptors and inhibitory cell signaling components. Additionally, ex-
pression of the BMP7 gene is tightly controlled both during embryonic development and adult life. In this review, the cur-
rent status of work on regulation of BMP7 at the genomic level is discussed. In situ hybridization and reporter gene stud-
ies have conclusively defined patterns of BMP7 expression in many tissues. Additionally, both in vivo and cell culture 
studies have defined some of the mechanistic bases for this regulation. In addition to transcriptional activation mediated 
by binding of activating transcription factors, there is also strong evidence for repression through recruitment of histone 
modifying enzymes to specific genetic elements. This review summarizes our current understanding of BMP7 gene regu-
lation in embryonic development and adult tissues. 
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BMP7 IN DEVELOPMENT AND DISEASE 
  The bone morphogenetic proteins (BMPs) were first 
identified as a group of osteoinductive proteins isolated from 
bovine bone [1]. Subsequent studies have shown that BMPs 
function as regulators of diverse developmental processes. 
Inactivation of Bmp7 reveals requirements for this gene in 
development of the kidney, eye, hindlimb [2, 3], lacrimal 
gland [4], and brown adipose tissue [5]. Compound inactiva-
tion with other Bmps or BMP modulators demonstrates addi-
tional functions in heart development [6], ventral mesoderm 
specification [7], and limb patterning [8]. As the Bmp7 null 
mutant is not viable, functions in the adult have been charac-
terized largely by in vitro experiments. In the kidney, BMP7 
is thought to prevent and perhaps even reverse the epithe-
lium to mesenchyme transition associated with fibrotic con-
ditions [9, 10], and counteract diabetic nephropathy [11, 12]. 
BMP7 also accelerates bone differentiation and fracture heal-
ing [13, 14], a feature that is currently being therapeutically 
exploited. 
OVERVIEW OF BMP SIGNALING 
  BMPs belong to the Transforming Growth Factor  
(TGF) superfamily of cytokines that regulate an array of 
fundamental cellular processes, including proliferation, dif-
ferentiation and cell death. Signaling is initiated when 
ligands bind cell surface serine threonine kinase BMP recep-
tors (BMPRs). A complex of type I and type II receptors is 
formed, in which the constitutively active BMPRII phos- 
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phorylates BMPRI, which in turn phosphorylates the recep-
tor associated transcription factors SMAD 1, 5 and 8 (R-
SMADs) [15, 16]. Phosphorylated R-SMADs associate with 
the common SMAD, SMAD4 [17] and are translocated into 
the nucleus where they bind DNA in association with other 
factors. Transcriptional outcomes are determined by associa-
tion with general transcriptional activators such as p300 and 
CBP [18], or by association with repressors such as Suv39h 
[19] or CtBP [20]. In addition to activating SMAD-depen- 
dent intracellular signaling, BMPs also activate p38 and JNK 
pathways through BMP-receptor associated TGF activated 
kinase 1 (TAK1) [21-23]. Regulation of the balance between 
activation of these two distinct intracellular cascades is in-
completely understood. Essential signaling components such 
as SMADs [24] and TAK1 [21, 25] are differentially ex-
pressed, influencing the potential for activation of these sig-
naling cascades by BMPs in distinct cell types. Additionally, 
it has been shown that the mode of physical interaction be-
tween BMPRI and BMPRII receptors influences signaling 
outcome following ligand binding. Activation of preformed 
BMPRI/RII complexes at the cell surface results in SMAD 
activation, whereas ligand-induced assembly of BMPRI/RII 
complexes preferentially results in MAPK activation [26]. 
Factors that differentially regulate the mode of receptor 
complex formation have not yet been identified. Although 
SMAD-dependent and SMAD-independent signaling path-
ways promote distinct transcriptional outcomes, it appears 
that these intracellular cascades function cooperatively in 
numerous contexts [21, 27-29].  
THE BMP LIGANDS 
  In the mouse, 17 distinct proteins are classified as BMPs 
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have been most extensively studied. On the basis of se-
quence similarity with prototypic Drosophila family mem-
bers, vertebrate BMPs can be divided into two sub-groups, 
which share approximately 30% identity at the amino acid 
level. The vertebrate BMP2 and BMP4 genes are functional 
orthologues of Drosophila Decapentaplegic (Dpp), whereas 
the vertebrate BMPs 5, 6 and 7 and the fly ligand Glass bot-
tom boat (Gbb) constitute a distinct sub-group. The conser-
vation of these separate BMP sub-groups across a wide 
phylogenetic distance suggests that dpp/BMP2/BMP4 and 
gbb/BMP5/BMP6/BMP7 may be functionally distinct. In 
Drosophila development, a balance between Dpp and Gbb is 
required for morphogenesis of the wing imaginal disk [31], 
indicating differential biological effects of these two ligands. 
Functional divergence of the two ligands associates with 
specificities for distinct receptors: Dpp primarily signals 
through the Thickveins (Tkv) receptor, whereas Gbb signals 
through both the Tkv and the Saxophone (Sax) receptors 
[32]. The combinatorial signaling outcome displays a coun-
terintuitive complexity, as Sax functions both as a positive 
mediator of Gbb signaling, and also as a negative regulator, 
sequestering this ligand and preventing it from signaling 
through Tkv [33]. Although the relationships between 
ligands and receptors in the mammalian signaling system is 
more difficult to interpret due to extensive redundancy, 
ligand-receptor interactions do display differential affinities, 
indicating that similar combinatorial interactions may regu-
late ligand interpretation by cells. Specifically, BMP4 binds 
the BMPRIs ALK3 and ALK6 strongly, whereas BMP7 effi-
ciently binds the BMPRIs ALK6 and ALK2 [34, 35]. ALK2 
is the ortholog of Sax, and it is therefore tempting to specu-
late that it may function similarly as both a signal transducer 
and antagonist. Signaling output from the receptor does dif-
fer depending on the identity of the associated BMPRII re-
ceptor [35]. However, combinatorial inactivation of recep-
tors in mesenchymal stem cells using an RNAi approach 
does not reveal an antagonistic effect of ALK2 in combina-
tion with any BMPRII receptor, arguing against conservation 
of the Dpp/TKV versus Gbb/Sax paradigm, at least in this 
cellular context [36]. A genetic test of this hypothesis has 
been conducted in the mouse by conditional inactivation of 
Alk2 and Alk3 either separately or in combination in the 
mouse Müllerian duct [37]. BMP signaling is required for 
Müllerian duct involution in the male, and provides a sensi-
tive genetic system with which to assay signal transduction 
in vivo. Interestingly, the two BMPRI receptors promote 
BMP signaling in a redundant fashion, again arguing against 
any inhibitory activity of BMP5/6/7/ALK2. Despite the in-
teresting inference based on comparison with signaling in 
Drosophila, little concrete evidence of differing biological 
outcomes of distinct BMP-receptor pairings has been found 
in mammalian cells.  
SHARED VERSUS UNIQUE BIOLOGICAL PROPER-
TIES OF BMP7 
  To try to ascertain whether BMP ligands have distinct in 
vivo functions, a genetic complementation strategy has been 
used to functionally compare Bmp6, Bmp7, and Bmp4 [38]. 
The analysis was performed by comparing the potential of 
Bmp6 and Bmp4 to rescue embryonic kidney development in 
the Bmp7 null mouse strain. Both the closely related Bmp6, 
and the more distantly related Bmp4 are capable of substitut-
ing for Bmp7 in early kidney development, suggesting that 
distinct BMPs may be functionally interchangeable in vivo in 
this context. However, Bmp7 null mice expressing Bmp4 
from the Bmp7 locus are not viable, and it therefore remains 
likely that there also are unique functions of these ligands 
that are required for embryonic development. Functional 
differences between BMPs other than the above mentioned 
differences in receptor affinities have been demonstrated in 
vitro. The extracellular protein antagonist Noggin binds 
BMP4 with higher affinity than BMP7 [39]. Conversely, the 
antagonist Chordin-like 1 inactivates BMP7, but not BMP4 
[40]. These antagonists are differentially expressed during 
embryonic development and in the adult, potentially creating 
zones of activity of various BMPs. One consequence of re-
ducing availability of ligand may be to influence the balance 
between SMAD-dependent and SMAD-independent signal-
ing. Comparison of intracellular signaling promoted by vary-
ing concentrations of BMP7 reveal preferential activation of 
p38 MAPK signaling at low concentrations, and phosphory-
lated SMAD1/5/8 at high concentrations in collecting duct 
cells and proximal tubule cells of the adult kidney [41, 42]. 
A unique function has furthermore been proposed for BMP7 
in counteracting, and even reversing epithelial to mesenchy-
mal transition caused by TGF in epithelial cells of the kid-
ney by activating the E-cadherin gene [9, 43]. The signaling 
mechanism underlying this phenomenon has not yet been 
clarified, and remains puzzling since the activity is unique to 
BMP7 and cannot be reproduced with the closely related 
ligand BMP6 [9]. The feature may be unique to cell types 
used in the study however, as other authors have been unable 
to reproduce the result in primary human proximal tubule 
cells [44]. 
  A model consistent with data at hand would be that 
BMPs 5, 6 and 7 derive from a common ancestral BMP, are 
functionally interchangeable, and have evolved distinct par-
tially overlapping domains of expression through addition of 
unique genomic regulatory elements. Consistent with this 
idea, individual inactivation of these genes reveals pheno-
types that closely correspond with their domains of unique 
expression [2, 3, 45-47]. Furthermore, highly exacerbated 
phenotypes are revealed by compound mutation of the 
Bmp5, Bmp6 and Bmp7 genes, [6, 48], indicating that the 
collective expression of these ligands determines develop-
mental function in domains of overlapping expression.  
REGULATION OF THE GENE ENCODING BMP7 
BMP7 in the Mouse Genome 
  In the mouse, Bmp7 is composed of 7 exons located dis-
tally on chromosome 2 (Fig. 1A). This region is thought to 
contain a number of imprinted genes [49]. However, expres-
sion analysis shows that Bmp7 is expressed from both ma-
ternal and paternal alleles in weanling mice, indicating that 
the gene is not imprinted [49]. This analysis was conducted 
on kidney tissue, and it remains possible that imprinting oc-
curs in other tissues. Two different Northern analyses have 
each revealed transcription of four separate splice forms of 
Bmp7 in the embryonic mouse kidney, however the precise 
sizes of these transcripts are not in complete agreement. In 
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identified [50], whereas in another, 1.9 kb, 2.1 kb, 3.6 kb and 
3.8 kb transcripts were detected [51]. These distinct tran-
scripts all contain identical coding sequence but vary in their 
5’ and 3’ untranslated regions (UTRs) because of the use of 
two independent initiation sites and two termination sites 
[51]. Transcriptional initiation sites have been identified, but 
do not conform to the TATA/CAAT transcriptional initiation 
paradigm [51, 52]. They are located within a GC rich region 
that serves as a core promoter (Fig. 1A). Initiation from 
TATA-less promoters is generally not precisely regulated 
[53], providing a likely explanation for the prevalence of 
distinct initiation sites in Bmp7. Functional consequences of 
alternate polyadenylation have not been reported for Bmp7. 
However, comparison of RNA by Northern blot from adre-
nal and kidney of newborn mice shows that long isoforms 
predominate in the adrenal, but both isoforms are almost 
equally represented in the kidney [50], indicating that there 
may be tissue-specific polyadenylation site preferences.  
 Expression  of  Bmp7 is strictly transcriptionally regulated 
both during development, and in the adult. Early studies em-
ploying in situ hybridization revealed that although Bmp7 is 
expressed in most organ systems, the pattern of expression 
within each organ system is intricately regulated [47, 54, 55]. 
The development of a reporter mouse strain expressing -
galactosidase from the Bmp7 locus has facilitated more spa-
tially precise expression analysis [56]. Transcription of 
Bmp7 has been most comprehensively studied in the kidney 
where gene expression has been mapped in detail from the 
earliest stages of development to the adult (Fig. 2). The per-
manent kidney of the mouse develops from two major cell 
lineages, which are both derived from intermediate meso-
derm. The nephron lineage forms all segments of the neph-
ron, or filtering unit, while the collecting duct lineage is 
fated to become the collecting system of the adult kidney 
[57-60].  Bmp7 is expressed in collecting ducts throughout 
development [47, 56], and remains actively expressed in 
collecting ducts of the adult [61]. In contrast, expression in 
the nephron lineage is highly dynamically regulated: al-
though progenitor cells of the developing nephron uniformly 
express Bmp7, only 2 specific cell types within the nephrons 
derived from these cells express the gene: podocytes of the 
glomerulus, and distal tubule cells [56, 61]. Whether Bmp7 
expression is inactivated upon differentiation of nephron 
progenitors, and subsequently reactivated in these differenti-
ated cell types, or whether it is maintained in a subset of des-
ignated progenitors throughout their differentiation is un-
clear. Other organ systems have similarly complex patterns 
of expression, possibly reflecting the evolution of BMP7 as a 
morphogen, with separate populations producing the ligand, 
and others receiving it.  
 Regulation  of  Bmp7 expression has been studied in the 
developing limb and kidney. Screening of the region sur-
rounding exon 1 using transgenic reporter mice reveals tissue 
specific regulatory elements for expression in eye, kidney, 
central nervous system and limb [51], encompassing a sig-
nificant proportion of all developmental expression of Bmp7. 
Closer analysis of expression in the kidney reveals that en-
hancer elements driving expression in nephron progenitor 
cells and in collecting duct cells are spatially separate. The 
collecting duct enhancer is located in intron 1 of the gene, 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Organization of BMP7 loci. A. Schematic of mouse Bmp7 depicting the functionally verified HOXA11 binding site, the G/C rich 
region surrounding the transcriptional initiation site, and the in vivo validated enhancer island controlling expression in kidney collecting 
duct, limb mesenchyme, and iris. B. Schematic of human BMP7 showing the approximate locations of the silencer element, the 
LMO4/Clim2 binding site, PAX2/6 binding sites, and the G/C rich region surrounding the promoter. Enhancer and repressor elements in the 
human locus have been identified and validated in vitro.  226    Current Genomics, 2009, Vol. 10, No. 4  Leif Oxburgh 
and mutational analysis reveals that it corresponds to a 
FOXD3 binding site. Since FOXD3 expression is limited to 
neural crest during development, it is most likely that a tran-
scription factor with a similar binding site is activating Bmp7 
transcription in kidney collecting ducts. In addition to the 
collecting duct, the FOXD3 binding site also regulates gene 
expression in specific domains of the limb and eye, and can 
be found within an approximately 500 bp enhancer island 
that displays 80% identity at the nucleotide level with ge-
nomes as evolutionarily distant as Xenopus tropicalis. 
Analysis of the remaining locus does not reveal any further 
islands of intronic sequence over 20 base pairs in length that 
are conserved to a similar degree with X. tropicalis. A ques-
tion that remains to be explored is whether additional regula-
tory sequence is located distant from the locus, as has been 
observed for the Bmp4 and Bmp5 genes [62, 63]. Close scru-
tiny of expression in the developing limb was prompted by 
studies of a mouse strain  null for the gene encoding the 
HOXA13 transcription factor. This mutant strain displays 
defects in separation of the digits, a process that BMP signal-
ing is known to regulate [64, 65]. Hoxa13, Bmp2 and Bmp7 
are expressed in an overlapping manner in interdigital mes-
enchyme, and disruption of Hoxa13 significantly reduces 
both Bmp2 and Bmp7 expression [66]. Using a synthetic pep-
tide mimicking the DNA binding activity of HOXA13, an 
enhancer element was located approximately 3 kb upstream 
of the promoter region. HOXA13 binding at this site was 
confirmed by chromatin immunoprecipitation [66]. Cell type 
specific regulation of Bmp7 by HOXA13 may occur in addi-
tional tissues, as dysregulation of Bmp7 has also been ob-
served in the genitourinary tract of Hoxa13 mutant mice 
[67].  
  Studies of regenerating adult mouse kidneys recovering 
from ischemically induced experimental injury show an in-
creased overall level of histone acetylation relative to unin-
jured controls, with a concomitant reduction in histone 
deacetylase 5 (HDAC5) expression [68]. Interestingly, 
siRNA mediated knock down of HDAC5 increases Bmp7 
expression in the rat kidney epithelial cell line NRK-52, in-
dicating that the gene may normally be repressed through 
histone modification, and that this might be reversed in the 
regenerative response. Studies of the dynamics of Bmp7 ex-
pression in the kidney following acute ischemia have yielded 
conflicting results, with Northern analyses demonstrating a 
significant decrease by 48 hours post ischemia, and a return 
to baseline levels approximately 7 days after injury [69]. 
Immunohistochemical studies on the other hand show a sub-
stantial increase 48 hours post ischemia [70]. This discrep-
ancy does not appear to reflect analysis of different regions 
of the kidney in these two studies, as both focused on the 
medulla. Further inquiry will be required to fully character-
ize  Bmp7 expression in the regenerative response, and to 
understand whether histone acetylation is a mechanism to 
promote production of reparative growth factors such as 
BMP7 in injured tissue. 
BMP7 in the Human Genome 
 BMP7 is located on chromosome 20 [71]. Two BMP7 
transcripts of approximately 2.2 kb and 4 kb can be detected 
in a variety of fetal tissues [55], and in cultured kidney cells 
[72] (Fig. 1B). Library screening of cDNA derived from 
polyadenylated transcripts identifies one approximately 2 kb 
transcript [73]. Subsequent analysis of cDNA sequences de-
posited at NCBI identify an additional 4 kb transcript with 
identical coding sequence, but longer 3’ UTR (NCBI acces-
sion number NM_001719). Promoter analysis reveals a sin-
gle transcriptional initiation site [74], and it can therefore be 
concluded that the difference in molecular weight between 
the two prevalent mRNA species is due to the usage of alter-
nate polyadenylation sites. Comparison with the mouse re-
veals approximately 75% identity in the 750 bp immediately 
preceding the transcriptional initiation site, a similar GC-rich 
nucleotide composition and a lack of TATA/CAAT motifs 
[74] (Fig. 3). Deletion analysis demonstrates the presence of 
a core promoter spanning approximately 600 bp of sequence 
immediately upstream of the transcriptional initiation site, 
and also shows that the activity of this promoter is strongly 
negatively regulated by silencer elements immediately up-
 
 
 
 
 
 
 
Fig. (2). Cell type specific control of Bmp7 transcription in the developing kidney. At early stages of kidney development, Bmp7 is ex-
pressed in both the collecting duct and nephron progenitors. Upon induction of progenitors to form a renal vesicle, Bmp7 expression is re-
gionalized, and is limited to the portion of the renal vesicle fated to form the distal nephron. As the renal vesicle progresses to the S-shaped 
body stage, distal expression of Bmp7 is maintained, and a small population of presumptive podocyte cells adjacent to the endothelial cleft at 
the proximal pole of the developing nephron also express Bmp7. This expression pattern is maintained throughout growth of the nephron, 
and the complex morphogenesis of the glomerulus. Abbreviations: DT, distal tubule; G, glomerulus; P, podocyte, PT, proximal tubule. Control of the BMP7 Gene in Development and Adult Life  Current Genomics, 2009, Vol. 10, No. 4    227 
stream [74, 75]. Comparison of BMP7 promoter activities in 
osteosarcoma Hos cell cells and kidney derived Cos-7 cells 
verifies the presence of silencer elements, but shows that 
their usage is cell type specific, with Hos cells demonstrating 
a strong silencing effect [75]. Analysis of the BMP7 pro-
moter in mammary tumor epithelial cells reveals binding of 
the LIM-only protein 4 (LMO4) within the silencer region 
[76]. LMO4 is a non-DNA binding protein that associates 
with DNA through interaction with other transcription fac-
tors. By combining chromatin immunoprecipitation with the 
use of a doxycycline-regulated LMO4-expressing cell line, 
the authors were able to show that low level binding of 
LMO4 in complex with the transcription factor Clim2 in the 
basal, non-activated state promotes recruitment of histone 
deacetylase 2 (HDAC2), thus potentially silencing transcrip-
tion through histone modification. Extensive binding of 
LMO4/Clim2 in the activated state instead reduces recruit-
ment of HDAC2, thus potentially relieving transcriptional 
silencing. 
  As in the mouse, tissue and cell type specific regulation 
of BMP7 is best understood in the kidney. At 6.5 weeks of 
development, intense BMP7 expression can be seen in neph-
ron progenitors and collecting ducts, while at 10 weeks ex-
pression has resolved to podocytes of the glomeruli, and re-
gions of the tubular nephron. The latter have not been de-
fined by marker analysis as distal tubules, but in analogy 
with the mouse, it seems highly likely that it is the distal 
nephron segment that expresses BMP7 [55]. Indeed, immu-
nohistochemical localization of BMP7 in the adult confirms 
protein expression in the distal tubule. Surprisingly, protein 
cannot be identified in adult human podocytes [77]. This 
may reflect a genuine species difference between mouse and 
human, but is perhaps more likely to reflect a lack of BMP7 
translation in the podocyte as both species demonstrate in-
tense mRNA expression in this cell type during late gesta-
tion. Regulation of cell type specific transcription is less well 
defined  in vivo for human BMP7 than for the mouse 
ortholog, but studies have identified regulatory circuits in 
cultured cells. Deletion analysis has determined that both 
PAX2 and PAX6 function as activators of BMP7 transcrip-
tion in in vitro transcriptional activation assays of the ge-
nomic region immediately upstream of the core promoter 
[74]. This is potentially important for the understanding of 
transcriptional regulation in the kidney as the PAX2 tran-
scription factor is absolutely required for normal kidney de-
velopment [78-80], and is expressed in an overlapping man-
ner with Bmp7 both in nephron progenitor cells and collect-
ing duct [81]. PAX2 is thus a strong candidate regulator of 
BMP7 expression in nephron progenitors.  
COMPARATIVE ASPECTS  
  As anticipated, extensive conservation is seen between 
mouse and human BMP7 loci. A dot-plot of nucleotide se-
quence identity in 15 kb of sequence surrounding the first 
exon demonstrates regions of approximately 80% identity 
for the Hoxa11 binding site, the core promoter, and the in-
tronic enhancer island regulating expression in kidney col-
lecting duct, limb mesenchyme and iris (Fig. 3). BMP7 may 
thus largely be controlled by similar transcriptional circuitry 
in the two species. One notable exception, however, is the 
silencer region preceding the core promoter of human BMP7. 
Interestingly, this region is almost completely divergent in 
the mouse upstream region. To ascertain whether this si-
lencer region is located elsewhere within the mouse Bmp7 
locus, dot plots comparing the human silencer region with 
the entire Bmp7 locus including all upstream and down-
stream intergenic sequence were generated. No region of 
greater than 30 nucleotides with 60% or better identity could 
be located on either strand, and it thus appears that this regu-
latory element is absent in mouse Bmp7. The finding that the 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Human-mouse comparison of the region surrounding exon 1. Comparison using a window size of 30 nucleotides and a mini-
mum identity of 60% reveals extensive conservation between mouse (x-axis) and human (y-axis) loci. Regions of specific interest are 
shaded: the regulatory elements are shaded dark grey, and exon 1 is shaded light grey. Although there is a high level of sequence conserva-
tion between species at these sites, there is little or no conservation within the region containing silencer elements identified in the human 
gene. 228    Current Genomics, 2009, Vol. 10, No. 4  Leif Oxburgh 
silencer element is utilized in Hos ostesarcoma and G401 
rhabdoid kidney tumor cell lines, but not in normal trans-
formed Cos-7 kidney cells [74, 75] demonstrates cell-type 
specificity and argues that it is not part of the core promoter 
sequence. The association of this region with LMO4/Clim2 
and histone deacetylase in human mammary tumor epithelial 
cells [76] furthermore provides a molecular mechanism for 
transcriptional control of the gene by the silencer element. 
However, the paucity of knowledge regarding in vivo gene 
regulation of human BMP7 precludes prediction of the role 
of this regulatory sequence in embryonic development or 
homeostasis of the adult. Further studies comparing the regu-
latory function of the silencer between cell lines derived 
from normal human tissue are necessary to better understand 
cell-type specific control of BMP7 by this fascinating ele-
ment. 
FUTURE PERSPECTIVES 
  Although relatively few studies have analyzed genomic 
regulation of the BMP7 gene, a complex and interesting pic-
ture is emerging. Studies using genetically modified mice to 
map the regulatory functions of non-coding sequence are 
labor intensive, but have been highly informative. The avail-
ability of genome sequences from multiple species now al-
low for high resolution in silico prediction of regulatory se-
quence by species comparison. Identification of fewer candi-
date elements with a higher degree of confidence will speed 
in vivo validation, and enable a more global understanding of 
transcriptional networks controlling Bmp7 in specific cells 
and tissues. 
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ABBREVIATIONS 
BMP =  Bone  Morphogenetic  Protein 
BMPR =  BMP  receptor 
bp =  Base  pairs 
HDAC =  Histone  deacetylase 
kb =  Kilobases 
R-SMAD =  Receptor  associated  Smad 
TAK1 =  TGF associated kinase 1 
TGF  =  Transforming Growth Factor  
UTR =  Untranslated  region 
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